Total Funding
53
12
Total FundingSeries A raised
Growth Score
-7 pts
Heat Score
-19 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
112813
Prominex is focused on the development and manufacture of molecular diagnostic assays for Point-of-Care (POC) infectious disease testing.
Paul G. Thomas: Founder and Chief Executive OfficerPast Role: Roka Bioscience, Founder & CEO
Paul Gargan: Co-Founder and Chief Commercial Officer
About the Company
Prominex is moving forward with ambitions to develop a 5-minute SARS-CoV-2 test on their point-of-care molecular diagnostic platform. The company is dedicated to increasing access to low-cost, quick infectious disease diagnostics for STIs and respiratory illnesses. Our SARS-CoV-2 test provides accurate results in 5 minutes, allowing healthcare
practitioners to make more informed treatment and infection management decisions. devoted to increasing access to low-cost, quick infectious disease tests for STIs and respiratory illnesses. Our SARS-CoV-2 test provides accurate results in 5 minutes, allowing healthcare practitioners to make more informed treatment and infection management decisions.
